Tarlatamab
Multispecific antibody
Evidence outlook
Approved: Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
- Treatment of small cell lung cancer that has progressed after cancer chemotherapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05060016 NCT05060016 · Small Cell Lung Cancer Registry: NCT05060016 | 2 | Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator (Up to a maximum of 61 months); Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events (Up to a maximum of 61 months); Part 1 Only: Serum Concentrations of Tarlatamab (Up to a maximum of 24 months); Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) (Up to a maximum of 61 months) 2027-12-30 | In progress: results expected 30 Dec 2027 | not yet graded | link ↗ |
View 3 more trials
DeLLphi-304 NCT05740566 · Small Cell Lung Cancer (SCLC) Patients were randomized 1:1 against an active chemotherapy comparator and the primary endpoint, overall survival, is the hardest cancer outcome. The result was statistically significant in 509 patients. The study had no blinding, so it is graded moderate and not strong. Registry: NCT05740566 | 3 | Overall Survival (OS) (From randomization up to minimum of death or primary completion DCO date 29 January 2025; median (min, max) time on the study was 8.6 (0.1, 18.5) months) 2025-01-29 | Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025). | Partial signal | link ↗ |
DeLLphi-305 NCT06211036 · Extensive-Stage Small-Cell Lung Cancer This was a randomized, open-label Phase 3 trial with 563 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate. Registry: NCT06211036 | 3 | OS (Up to approximately 3 years) 2030-04-02 | Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08). | Partial signal | link ↗ |
NCT06117774 NCT06117774 · Limited Stage Small Cell Lung Cancer Registry: NCT06117774 | 3 | PFS as Determined by BICR (Up to approximately 6 years); OS Over the Whole Trial (Up to approximately 6 years) 2030-04-20 | In progress: results expected 20 Apr 2030 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tarlatamab: this drug | Approved | Multispecific antibody | DLL3 and CD3 | Partial signal | NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08). NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025). | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Lurbinectedin | Approved | Small molecule | Alkylating Drug | Partial signal | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-706 | Phase 3 | Antibody–drug conjugate | SEZ6 | not yet graded | No reviewed efficacy summary in this indication | |
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| AL8326 | Phase 3 | Small molecule | Aurora B / FGFR / VEGFR (multi-kinase) | Weak signal | NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022) | |
| Atigotatug | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Gocatamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Obrixtamig | Phase 3 | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Pumitamig | Phase 3 | Multispecific antibody | PD-L1 and VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Risvutatug Rezetecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Serplulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tislelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alisertib | Phase 2 | Small molecule | Aurora kinase A (AURKA) | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986525 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| DJI136 | Phase 1/2 | Cell therapy | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Quaratusugene Ozeplasmid (Reqorsa) | Phase 1/2 | Gene therapy / editing | TUSC2 (tumor suppressor gene replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(35 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tarlatamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (10)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (6)
March 2028 (2)
April 2028 (2)
May 2028 (1)
What to watch
October 2028 (1)
2029 (8)
January 2029 (1)
What to watch
February 2029 (2)
April 2029 (1)
What to watch
May 2029 (1)
What to watch
August 2029 (1)
What to watch
2030 (7)
April 2030 (2)
May 2030 (2)
What to watch
What to watch
June 2030 (2)
August 2030 (1)
What to watch
2031 (3)
June 2031 (2)
August 2031 (1)
What to watch
2037 (1)
November 2037 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent